Oral aminaphtone plus topical lidocaine for internal hemorrhoids
Official title: Observational Study on the Effectiveness of a First-line Therapy With Aminaphtone and Lidocaine Cream in Patients With Hemorrhoidal Disease: a Prospective Monocentric Cohort Study
Run by Treviso Regional Hospital · NCT07026513 · Data updated 2026-11-12
This study will try an oral aminaphtone pill together with a lidocaine cream to reduce symptoms in adults with internal hemorrhoids compared with standard conservative care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Treviso Regional Hospital Research network |
| Locations | 1 site (Treviso) |
| Status | Recruiting |
| Started | May 8, 2025 |
| Main results expected | July 15, 2025 |
| Study ends | July 31, 2025 |
| Registry record updated | June 18, 2025 |
| Trial ID | NCT07026513 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–85 with symptomatic internal hemorrhoidal disease (Goligher grades I–IV) presenting for their first outpatient consultation for the current symptoms who can give written informed consent.
✕Probably not a fit
Patients with active proctologic conditions (fissures, fistulas, condylomas, neoplasms), inflammatory bowel disease, known HIV infection, recent hemorrhoidal surgery, current immunomodulatory/corticosteroid/antibiotic/antifungal/psychotropic therapy, or known allergy to Capillarema® or Octosedan® components are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
ORACLE is a prospective, single-center observational study at Treviso Regional Hospital enrolling adults with symptomatic internal hemorrhoidal disease (Goligher I–IV). Patients in routine outpatient care will receive either oral aminaphtone (Capillarema®) combined with a topical lidocaine cream (Octosedan®) or standard advice on diet and hydration with optional topical emollients and lidocaine. Investigators will follow participants for 30 days to record symptom changes, tolerability, and any need for additional treatments using clinical assessments and patient-reported outcomes. The design captures real-world effectiveness and safety rather than results from a randomized trial.
Why it matters
Potential benefit: If successful, the combination could reduce bleeding and pain and improve quality of life, offering a more effective first-line conservative option and potentially lowering the need for procedural interventions.
How similar studies have gone: Aminaphtone has shown benefit in chronic venous and microvascular conditions and topical lidocaine is established for anal pain, but their combined use for hemorrhoidal disease is novel with limited direct evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 to 85 years * Diagnosis of symptomatic internal hemorrhoidal disease (Grade I-IV, Goligher classification) * First outpatient consultation for current symptoms * Written informed consent provided Exclusion Criteria: * Active proctologic conditions (e.g., anal fissures, fistulas, condylomas, neoplasms) * Inflammatory bowel disease (IBD) * Known HIV infection * Previous surgical treatment for hemorrhoidal disease (except outpatient procedures performed \>6 months prior) * Current use of psychotropic, antibiotic, antifungal, immunomodulatory, or corticosteroid drugs * Known hypersensitivity to Capillarema® or Octosedan® components
Where it's running
-
Regional Hospital Treviso
Treviso, Italy Recruiting
Study contacts
- Study coordinator: Ugo Grossi, PhD
- Email: ugo.grossi@aulss2.veneto.it
- Phone: +39-3291649443
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hemorrhoid Artery Embolization (HAE) for Bleeding Internal Hemorrhoids: A Real-World Registry
This registry collects real-world data to see if hemorrhoid artery embolization helps adults with symptomatic internal hemorrhoids that haven’t improved with standard care.
-
SHAPE vs. Milligan-Mordon hemorrhoidectomy for advanced hemorrhoids
This trial tests whether Skin-Sparing Hemorrhoidectomy and PExy (SHAPE) works as well as the conventional Milligan-Morgan procedure for adults with severe hemorrhoids.
-
Topical nifedipine 0.3% plus lidocaine 1.5% for uncomplicated hemorrhoids
This will try topical nifedipine 0.3% plus lidocaine 1.5% applied rectally and perianally twice daily to reduce symptoms in adults with uncomplicated acute hemorrhoids.
-
Lignocaine versus GTN ointment for pain after hemorrhoidectomy
This test compares lignocaine ointment and 0.2% glyceryl trinitrate (GTN) ointment to see which provides better pain relief for adults after hemorrhoidectomy.
-
Neoven (Ruscus aculeatus 225 mg) capsules for adults with stage II–III hemorrhoids
This test will see if Neoven (Ruscus aculeatus 225 mg) capsules reduce symptoms in adults aged 18–45 with stage II–III hemorrhoids.
-
Investigating the link between cough and hemorrhoids
This study is trying to see if having a cough might be linked to developing hemorrhoids in patients visiting the hospital for this condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.